A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A phase 3 trial of Tucatinib, Trastuzumab, Bevacizumab, Cetuximab and Oxaliplatin in colorectal cancer, run by Seagen, a wholly owned subsidiary of Pfizer, now recruiting.
Overview
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05253651 by Seagen, a wholly owned subsidiary of Pfizer, with 400 participants planned, started 2022-10-24 and due to reach its primary completion in 2027-12-31. Interventions recorded: tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin and leucovorin.
Similar pages
not linked directly; found by shared links- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Oxaliplatin, Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialAK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Shares Oxaliplatin, Cetuximab, Colorectal cancer and the tag pipeline.
- TrialSafety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Shares Oxaliplatin, Trastuzumab, Bevacizumab and the tag pipeline.
- TrialA Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Shares Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Trastuzumab and the tag pipeline.